抗肺动脉高压药物及其作用机制研究进展  

Research progress of anti-pulmonary arterial hypertension drugs and its mechanism

作　　者：王冉冉 方莲花[1] 杜冠华[1] WANG Ran-ran;FANG Lian-hua;DU Guan-hua(Beijing Key Lab of Drug Target Identification and Drug Screening,Institute of Materia Medica,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院北京协和医学院药物研究所,北京市药物靶点研究与新药筛选重点实验室,北京100050

出　　处：《中国药理学通报》2020年第7期893-897,共5页Chinese Pharmacological Bulletin

基　　金：中国医学科学院医学与健康科技创新工程项目(No.2017-I2M-1-010,2016-I2M-3-007);国家自然科学基金资助项目(No.81773935);国家科技重大专项(No.2018ZX09711001-001-014,2017ZX09101001)。

摘　　要：肺动脉高压是一种慢性的严重心肺功能障碍性疾病,其病理机制尚不明确,病因复杂,死亡率高。目前临床上常用药物主要以舒张血管机制药物为主,包括钙离子通道阻滞剂、靶向NO/cG MP通路激活剂、内皮素受体拮抗剂和前列环素类似物等。但是这些治疗药物疗效有限,价格昂贵,不良反应较多,急需研发疗效更好、更安全的药物。该文查阅近年来国内外研究文献,总结了肺动脉高压发生和发展的生理病理机制、肺动脉高压的常用治疗药物类型及作用机制,以及正在研发中的新型药物,以期为今后肺动脉高压治疗药物的研究和开发提供参考。Pulmonary arterial hypertension is one of chronic severe cardiopulmonary dysfunctional diseases.Accompanied with high mortality and complex etiology,the mechanism of pulmonary arterial hypertension is still unclear.At present,the most commonly used drugs in clinical practice are mainly vasodilators,including calcium channel blockers,targeted NO/cGMP pathways potentiators,endothelin receptor antagonists,and prostacyclin analogs.However,safer and better curative drugs are in urgent need due to limited curative effects,high price,many adverse reactions and poor prognosis of patients.Based on the research at home and abroad in recent years,in this review we summarize the pathophysiological mechanisms,commonly used anti-pulmonary arterial hypertension drugs and new drugs under development to provide reference for the future research on drugs.

关 键 词：肺动脉高压 血管重构 药物 作用机制 舒张血管 联合治疗 

分 类 号：R322.121[医药卫生—人体解剖和组织胚胎学] R544.022[医药卫生—基础医学]